Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...
Hosted on MSN10d
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...
Pen Needles Market to Hit USD 3.08 Billion by 2030 with 9.2% CAGR | MarketsandMarkets
The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 Billion in 2024 ...
NBC Los Angeles7d
Hims & Hers faces scrutiny from senators on Super Bowl ad that ‘risks misleading' patients
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
News243d
Which of the breakthrough weight-loss medicines can you get in SA?
Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...
GlobalData on MSN4d
Super Bowl ad for copycat weight loss drugs stokes pharma power debate
Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...
AllAfrica.com8d
South Africa: Which of the Breakthrough Weight Loss Medicines Can You Get in SA?
Ozempic and Rybelsus are marketed by Novo Nordisk for treatment of type 2 diabetes, while Wegovy is marketed for weight loss. Ozempic and Wegovy are both weekly injections. Ozempic is sold in ...
Medscape1d
Room-temperature Storage of Medications Labeled for Refrigeration
28 days Prescribing information 70% insulin aspart protamine suspension and 30% insulin as part injection (rDNA origin) pen fill cartridge Novolog Mix 70/30 pen fill cartridge (Novo Nordisk ...